Background on Osimertinib Resistance Mechanisms and Unmet Needs Driving Evaluation of Novel Therapies

Opinion
Video

This segment introduces a discussion on the MARIPOSA-2 trial evaluating amivantamab plus chemotherapy or amivantamab, lazertinib and chemotherapy in EGFR-mutant NSCLC after osimertinib progression.

•How frequently does the disease develops resistance to osimertinib in the frontline setting?

•How does amivantamab address the unmet needs of patients who develop resistance to osimertinib?

Recent Videos
Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.
A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.
5 experts in this video
5 experts in this video
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content